FullText URL fulltext.pdf
Author Murakami, Hiroyuki| Matsuoka, Ken-Ichi| Asano, Takeru| Moriyama, Takashi| Matsumura, Akifumi| Fujiwara, Hideaki| Asada, Noboru| Ennishi, Daisuke| Nishimori, Hisakazu| Fujii, Keiko| Fujii, Nobuharu| Toji, Tomohiro| Yoshino, Tadashi| Maeda, Yoshinobu|
Keywords Refractory acute myeloid leukemia Transplant B-cell lymphoma-2 Azacitidine Venetoclax
Published Date 2022-11-08
Publication Title Case Reports In Oncology
Volume volume15
Issue issue3
Publisher Karger
Start Page 974
End Page 979
ISSN 1662-6575
NCID AA12780955
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2022 The Author(s).
File Version publisher
PubMed ID 36636684
DOI 10.1159/000526697
Web of Science KeyUT 000905485600025
Related Url isVersionOf https://doi.org/10.1159/000526697
FullText URL fulltext.pdf
Author Meguri, Yusuke| Asano, Takeru| Yoshioka, Takanori| Iwamoto, Miki| Ikegawa, Shuntaro| Sugiura, Hiroyuki| Kishi, Yuriko| Nakamura, Makoto| Sando, Yasuhisa| Kondo, Takumi| Sumii, Yuichi| Maeda, Yoshinobu| Matsuoka, Ken-Ichi|
Keywords regulatory T cell low-dose interleukin-2 therapy graft-versus-host disease graft-versus-leukemia effect transplantation tolerance
Published Date 2022-08-02
Publication Title Frontiers In Immunology
Volume volume13
Publisher Frontiers Media
Start Page 891925
ISSN 1664-3224
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2022 Meguri, Asano, Yoshioka, Iwamoto, Ikegawa, Sugiura, Kishi, Nakamura, Sando, Kondo, Sumii, Maeda and Matsuoka.
File Version publisher
PubMed ID 35983059
DOI 10.3389/fimmu.2022.891925
Web of Science KeyUT 000844642000001
Related Url isVersionOf https://doi.org/10.3389/fimmu.2022.891925
JaLCDOI 10.18926/AMO/54608
FullText URL 70_5_429.pdf
Author Asano, Takeru| Matsuoka, Ken-ichi| Iyama, Satoshi| Ohashi, Kazuteru| Inamoto, Yoshihiro| Ohwada, Chikako| Murata, Makoto| Satake, Atsushi| Yoshida, Chikamasa| Nakase, Koichi| Mori, Yasuo| Tanimoto, Mitsune|
Abstract Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.
Keywords chronic GVHD allogeneic HSCT steroid refractory IL-2
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-10
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 429
End Page 433
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777442
Web of Science KeyUT 000388098700019